A Study of HMPL-689 in Healthy Volunteers

HUTCHMED

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: HMPL-689; Drug: HMPL-689 placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02631642

2015-689-00AU2

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers

Full description

Subjects will receive a single dose of HMPL-689 or matching placebo during Day 1. The planned dose levels are: 1, 2.5, 5, 10, 20, 25 and 30 mg (about 7 cohorts of 8 subjects). In each dose cohort, 8 subjects will be randomized to receive HMPL-689 (6 subjects) or placebo (2 subjects) under fed condition with a standard meal.

For the first dose Cohort (1 mg), a sentinel group of 2 subjects (1 HMPL-689 and 1 placebo) will be dosed 24 hours prior to the planned dosing of the remaining six subjects. The decision of dose escalation or study termination will be made jointly by the principal investigator and the sponsor based on the clinical data (safety, tolerability, available PK data and clinical laboratory values). Any dose level may be repeated, reduced or split into 2 doses if deemed appropriate by the Principal Investigator and Sponsor's medical Expert.

Enrollment: 48 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Informed consent must be obtained in writing for all subjects before enrollment into the study
2. Healthy male subjects aged 18 to 45 years inclusive at the time of screening
3. Body mass index ≥19.0 and ≤ 30.0 kg/m2
4. Willing to comply with the contraceptive requirements of the study and must not donate sperm during the study or for 3 months afterwards. Subjects must agree to use a condom or to abstain from sexual intercourse throughout the trial and for 30 days afterwards

Exclusion criteria

1. Family history of premature Coronary Heart Disease

2. History of immunosuppression or opportunistic infections or receipt of a live virus vaccination within the 3 months prior to screening

3. Clinically significant abnormalities as determined by medical history physical examination, or laboratory test, especially for liver and renal function

4. Clinically significant findings in ECG, blood pressure and heart rate, as determined by the Clinical Investigator

5. Subjects at risk for tuberculosis (TB), which is defined as:

   1. Current clinical or laboratory evidence of active TB
   2. History of TB
   3. A positive QuantiFERON® test at screening or within 6 months prior to Day 1

6. Any medical condition requiring regular use of medication

7. Exposure to prescription medications within 30 days prior to Day 1

8. Exposure to any other medication, including over-the-counter medications, herbal remedies and vitamins 14 days prior to first dose (except for paracetamol)

9. Participation in another clinical trial with any investigational drug within 30 days of Day 1

10. Treatment in the previous 3 months with any drug known to have a well-defined potential for toxicity to a major organ

11. Current smoker of more than 10 cigarettes or equivalent/ day prior to commencing the study and unable to completely stop smoking during the study

12. Symptoms of a clinically significant illness in the 3 months before the study

13. Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs

14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, hemorrhoids or anal diseases with regular or recent presence of blood in feces

15. History of significant allergic disease (e.g. allergic to medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization/ enrollment or any food allergy

16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)

17. Current evidence of drug abuse or history of drug abuse within one year before randomization/ enrollment

18. Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study

19. Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study

20. Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

48 participants in 2 patient groups, including a placebo group

HMPL-689

Experimental group

Description:

Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.

Treatment:

Drug: HMPL-689

HMPL-689 placebo

Placebo Comparator group

Description:

Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.

Treatment:

Drug: HMPL-689 placebo